US Stock Movement: SELLAS Life Sciences plunges on November 19 due to discounted underwritten offering and significant price discount
Bitget异动解读2026/11/19 09:35SELLAS Life Sciences November 19 Sharp Decline Analysis
Keywords: discounted underwritten offering, significant discount pricing
1. On November 18, SELLAS announced an underwritten public offering of 11,538,462 shares of common stock at a price of $13.00 per share, raising a total of $150 million. The offering price represents a discount of about 28% compared to Wednesday’s closing price, significantly lower than the previous trading day's level of around $19, leading to concerns about dilution and putting pressure on the stock price.
2. On November 17, after the company announced positive topline data from its REGAL Phase 3 trial, the stock price surged about 156% in a single day. This discounted offering price stands in sharp contrast to the rapid price increase, making the scale of the pricing discount a key focus for the market.
(Disclaimer: This content is collected and summarized from publicly available information by AI technology, for reference only and does not constitute investment advice.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
New Zealand Dollar rebounds from levels near multi-year lows
Spot gold surpasses $3,730 per ounce, up 0.14% intraday

Dow Jones futures rise ahead of Anthropic IPO market debut
